

Rachael F F Grace

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1101738/publications.pdf>

Version: 2024-02-01

86
papers

2,776
citations

218677

26
h-index

189892

50
g-index

88
all docs

88
docs citations

88
times ranked

2897
citing authors

#	ARTICLE	IF	CITATIONS
1	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3829-3866.	5.2	684
2	The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , 2011, 152, 452-459.	2.5	216
3	Erythrocyte pyruvate kinase deficiency: 2015 status report. <i>American Journal of Hematology</i> , 2015, 90, 825-830.	4.1	140
4	Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1585-1588.	3.8	127
5	Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. <i>Blood</i> , 2015, 126, 873-879.	1.4	124
6	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. <i>Blood</i> , 2018, 131, 2183-2192.	1.4	121
7	Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. <i>New England Journal of Medicine</i> , 2019, 381, 933-944.	27.0	115
8	Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1194-1200.e1.	2.9	92
9	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1407-1413.	1.5	70
10	How we manage patients with pyruvate kinase deficiency. <i>British Journal of Haematology</i> , 2019, 184, 721-734.	2.5	66
11	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26736.	1.5	51
12	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. <i>Blood</i> , 2012, 119, 3263-3268.	1.4	48
13	Genetic studies in pediatric ITP: outlook, feasibility, and requirements. <i>Annals of Hematology</i> , 2010, 89, 95-103.	1.8	47
14	Red Blood Cell Enzyme Disorders. <i>Pediatric Clinics of North America</i> , 2018, 65, 579-595.	1.8	47
15	Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020, 95, 472-482.	4.1	47
16	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. <i>Haematologica</i> , 2019, 104, e51-e53.	3.5	46
17	Management of pyruvate kinase deficiency in children and adults. <i>Blood</i> , 2020, 136, 1241-1249.	1.4	42
18	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. <i>New England Journal of Medicine</i> , 2022, 386, 1432-1442.	27.0	42

#	ARTICLE	IF	CITATIONS
19	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	4.1	37
20	Second-line therapies in immune thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 698-706.	2.5	32
21	COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28382.	1.5	32
22	Treatment and outcomes of immune cytopenias following solid organ transplant in children. <i>Pediatric Blood and Cancer</i> , 2015, 62, 214-218.	1.5	31
23	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 306-314.	2.1	31
24	Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	4.1	30
25	The variable manifestations of disease in pyruvate kinase deficiency and their management. <i>Haematologica</i> , 2020, 105, 2229-2239.	3.5	30
26	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2012, 58, 221-225.	1.5	29
27	The burden of disease in pyruvate kinase deficiency: Patients' perception of the impact on health-related quality of life. <i>European Journal of Haematology</i> , 2018, 101, 758-765.	2.2	25
28	Unsuspected Pulmonary Emboli in Pediatric Oncology Patients: Detection With MDCT. <i>American Journal of Roentgenology</i> , 2010, 194, 1216-1222.	2.2	20
29	The role of romiplostim for pediatric patients with immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091299.	2.5	19
30	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 191, 98-106.	2.5	18
31	Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. <i>Pediatric Blood and Cancer</i> , 2012, 58, 216-220.	1.5	17
32	Comorbidities and complications in adults with pyruvate kinase deficiency. <i>European Journal of Haematology</i> , 2021, 106, 484-492.	2.2	17
33	Trends in anti-D immune globulin for childhood immune thrombocytopenia: Usage, response rates, and adverse effects. <i>American Journal of Hematology</i> , 2012, 87, 315-317.	4.1	15
34	The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. <i>British Journal of Haematology</i> , 2021, 192, 1092-1096.	2.5	15
35	Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26303.	1.5	14
36	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	3.8	14

#	ARTICLE	IF	CITATIONS
37	Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 81-83.	2.1	13
38	International survey on <i>Helicobacter pylori</i> testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 287-296.	3.8	13
39	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 69-80.	2.3	13
40	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. <i>Blood Advances</i> , 2022, 6, 1844-1853.	5.2	12
41	Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. <i>Pediatric Blood and Cancer</i> , 2009, 52, 865-867.	1.5	10
42	Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000885.	1.2	10
43	Pyruvate kinase deficiency in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29148.	1.5	10
44	The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. <i>European Journal of Haematology</i> , 2014, 93, 161-164.	2.2	9
45	Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease-specific assessments. <i>European Journal of Haematology</i> , 2020, 104, 427-434.	2.2	9
46	Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. <i>European Journal of Haematology</i> , 2021, 106, 783-787.	2.2	9
47	Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. <i>American Journal of Hematology</i> , 2019, 94, 461-466.	4.1	8
48	Characterization of the severe phenotype of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020, 95, E281.	4.1	8
49	An Update on Pediatric Immune Thrombocytopenia (ITP): Differentiating Primary ITP, IPD, and PID. <i>Blood</i> , 2021, , .	1.4	8
50	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2348-2354.	3.8	7
51	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 73-73.	1.4	6
52	Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29447.	1.5	6
53	The utility of the DDAVP challenge test in children with low von Willebrand factor. <i>British Journal of Haematology</i> , 2015, 170, 884-886.	2.5	5
54	Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. <i>Pediatric Neurology</i> , 2016, 62, 66-70.	2.1	5

#	ARTICLE	IF	CITATIONS
55	Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study. <i>Blood</i> , 2016, 128, 402-402.	1.4	5
56	Standardized Clinical Assessment and Management Plans (SCAMPs): Perspectives on a New Method to Understand Treatment Decisions and Outcomes in Immune Thrombocytopenia. <i>Seminars in Hematology</i> , 2013, 50, S31-S38.	3.4	4
57	Genetic variants in toll-like receptor 4 are associated with lack of steroid responsiveness in pediatric ITP patients. <i>American Journal of Hematology</i> , 2020, 95, 395-400.	4.1	4
58	Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	1.5	4
59	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2094-2095.	3.8	4
60	Response to rituximab in children and adults with immune thrombocytopenia (ITP). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12587.	2.3	4
61	Pk1r Intron Splicing-Associated Mutations and Alternate Diagnoses Are Common in Pyruvate Kinase Deficient Patients with Single or No Pk1r Coding Mutations. <i>Blood</i> , 2018, 132, 3607-3607.	1.4	4
62	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. <i>Blood</i> , 2015, 126, 3337-3337.	1.4	4
63	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. <i>American Journal of Hematology</i> , 2010, 85, 135-137.	4.1	3
64	Thrombopoietin-receptor agonists in children with immune thrombocytopenia. <i>Lancet, The</i> , 2015, 386, 1606-1609.	13.7	3
65	Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat. <i>Blood</i> , 2021, 138, 924-924.	1.4	3
66	Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (<scp>PKD</scp>): Toward an expanded definition of severe <scp>PKD</scp>. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
67	SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29760.	1.5	3
68	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopenia (ITP) in children: study protocol. <i>BMJ Open</i> , 2021, 11, e044885.	1.9	2
69	Pediatric Hematology. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, xiii-xiv.	2.2	1
70	Pyruvate kinase deficiency in a newborn with extramedullary hematopoiesis in the skin. <i>Blood</i> , 2020, 136, 770-770.	1.4	1
71	Preoperative hematocrit and platelet count are associated with blood loss during spinal fusion for children with neuromuscular scoliosis. <i>Journal of Perioperative Practice</i> , 2021, , 175045892096263.	0.5	1
72	Compliance with Immunizations in Splenectomized Individuals: A Study of the Splenectomized Hereditary Spherocytosis Population. <i>Blood</i> , 2008, 112, 1316-1316.	1.4	1

#	ARTICLE	IF	CITATIONS
73	DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2015, 126, 4548-4548.	1.4	1
74	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. <i>Blood</i> , 2015, 126, 2136-2136.	1.4	1
75	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2018, 132, 4807-4807.	1.4	1
76	The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis. <i>Blood</i> , 2019, 134, 2174-2174.	1.4	1
77	Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29410.	1.5	1
78	Rationale and Design of a Phase 3b Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Pediatric Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 4211-4211.	1.4	1
79	Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: An ITP Consortium of North America (ICON) Quality Improvement Initiative. <i>Blood</i> , 2021, 138, 755-755.	1.4	1
80	Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature. <i>Blood</i> , 2020, 136, 45-46.	1.4	1
81	Diagnosis, monitoring, and management of pyruvate kinase deficiency in children. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29696.	1.5	1
82	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. <i>Blood</i> , 2010, 116, 2509-2509.	1.4	0
83	Survey of 275 Patients and Caregivers Affected By Pyruvate Kinase Deficiency: Impact of Communication with Hematologists on Mental Health and Quality of Life. <i>Blood</i> , 2021, 138, 1948-1948.	1.4	0
84	Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry. <i>Blood</i> , 2021, 138, 3074-3074.	1.4	0
85	Characteristics of Children and Adults Treated with Rituximab for Immune Thrombocytopenia (ITP). <i>Blood</i> , 2020, 136, 38-39.	1.4	0
86	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. <i>Blood</i> , 2020, 136, 6-8.	1.4	0